NMD4C Launch New Multi-Disciplinary Care of Neuromuscular Diseases Education Curriculum
The NMD4C is excited to share a new training and education initiative from our education team! The Multi-Disciplinary Care of Neuromuscular Diseases lecture series is a new CPD-Accredited 24-topic webinar series designed as an advanced curriculum for neurologists, physiatrists and neuromuscular fellows to learn fundamentals of multi-disciplinary care for patients across a range of neuromuscular conditions.
Designed by physiatrist Dr. Jessica Thériault, the curriculum covers a broad range of competencies including systemic complications in NMDs to rehabilitation and psychosocial support.
By attending weekly sessions, clinicians can learn or refresh their knowledge to work more effectively with their centre’s multi-disciplinary care teams and inform their own practice in the case of neuromuscular specialists who are relied on to provide expansive multi-disciplinary care for their patients.
Access the Curriculum:
Live lectures will take place from 6-7 pm ET running from Wednesday January 15, 2025 to June 25, 2025. Neurologists, Physiatrists and neuromuscular fellows interested in attending the series are welcome to register here to receive a calendar invitation. Lecture recordings will also be uploaded to LEARNMD and available to NMD4C clinical and research members.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.